Karyopharm Therapeutics Pipeline & Clinical Trials

Description	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (penta-refractory) STORM¹^,² \| + dexamethasone	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (2L+) BOSTON¹^,³ \| + bortezomib and dexamethasone	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (2L+; post anti-CD38) XPORT-MM-031⁴^,^a^,^b \| + pomalidomide and dexamethasone View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Myelofibrosis (JAKi treatment-naïve) SENTRY⁵ \| + ruxolitinib View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Endometrial cancer (maintenance therapy; TP53 wild-type) XPORT-EC⁶ \| monotherapy View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Endometrial Cancer (maintenance therapy) SIENDO⁷ \| monotherapy	Phase 1	Phase 2	Phase 3	Market Approval
Myelofibrosis (JAKi treatment-naïve; moderate thrombocytopenia) SENTRY-2⁸ \| monotherapy View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (relapsed/refractory and frontline) STOMP⁹^,^c \| multiple agents View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval

Description	Phase 1	Phase 2	Phase 3	Market Approval
Myelodysplastic neoplasms (relapsed/refractory) KCP-8602-801¹⁰ \| monotherapy	Phase 1	Phase 2	Phase 3	Market Approval

Hematologic Malignancies

Solid Tumors

*Pipeline includes completed trials and trials in progress (last updated May 1, 2026). ^aSponsored by European Myeloma Network; EMN29. ^bVersus elotuzumab, pomalidomide, and dexamethasone. ^cSTOMP has a total of 12 arms; enrolling arm 12 only.

1. XPOVIO (selinexor) [package insert]. Newton, MA; Karyopharm Therapeutics.
2. ClinicalTrials.gov identifier: NCT02336815. https://clinicaltrials.gov/ct2/show/study/NCT02336815. Accessed May 1, 2026.
3. ClinicalTrials.gov identifier: NCT03110562. https://clinicaltrials.gov/ct2/show/study/NCT03110562. Accessed May 1, 2026.
4. ClinicalTrials.gov identifier: NCT05028348. https://clinicaltrials.gov/ct2/show/study/NCT05028348. Accessed May 1, 2026.
5. ClinicalTrials.gov identifier: NCT04562389. https://clinicaltrials.gov/ct2/show/study/NCT04562389. Accessed May 1, 2026.
6. ClinicalTrials.gov identifier: NCT05611931. https://clinicaltrials.gov/ct2/show/study/NCT05611931. Accessed May 1, 2026.
7. ClinicalTrials.gov identifier: NCT03555422. https://clinicaltrials.gov/ct2/show/study/NCT03555422. Accessed May 1, 2026.
8. ClinicalTrials.gov identifier: NCT05980806. https://clinicaltrials.gov/ct2/show/study/NCT05980806. Accessed May 1, 2026.
9. ClinicalTrials.gov identifier: NCT02343042. https://clinicaltrials.gov/ct2/show/study/NCT02343042. Accessed May 1, 2026.
10. ClinicalTrials.gov identifier: NCT02649790. https://clinicaltrials.gov/ct2/show/study/NCT02649790. Accessed May 1, 2026.

Clinical Trials

Find more information about ongoing clinical trials evaluating Karyopharm’s investigational medicines.